Stella Pharma Corporation
Notice Regarding Scheduled Deliberation at the Pharmaceutical Affairs and Medical Devices Council for Steboronin® for Recurrent Meningioma
Notice of scheduled deliberation at the BNCT pharmaceutical affairs council. A partial change application to the marketing authorization for Steboronin® to include recurrent meningioma has been submitted and is scheduled for deliberation by the Council’s Second Subcommittee. The impact on the fiscal year ending March 2027 is expected to be minimal.
Key Figures
- Unknown: No financial metrics disclosed other than company name and official title
- Unknown: Specific date/time of the scheduled deliberation has been announced but numeric details are unspecified
- Unknown: The impact on the fiscal year ending March 2027 is described as minimal, but amounts are unspecified
AI要約
Key Points
A partial change application to the marketing authorization for Steboronin® to include recurrent meningioma has been submitted. The Ministry of Health, Labour and Welfare has announced that this application is scheduled for deliberation by the Pharmaceutical Affairs and Medical Devices Council’s Second Subcommittee. Measures to expand indications in the BNCT field continue, contributing to the company’s growth strategy pillar of indication expansion. Deliberation results and future disclosures will be announced as appropriate.
Outlook and Impact
The impact on the fiscal year ending March 2027 is expected to be minimal, and additional disclosures may be made depending on the council’s conclusion. The company will continue initiatives to expand indications and promote overseas deployment as efforts to broaden market and treatment options.
Stella Pharma Corporation
Company overview · Stock price · Financial data · All IR
